Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$86.53 USD
+0.55 (0.64%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $86.49 -0.04 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth B Momentum F VGM
Zacks News
Best Momentum Stocks to Buy for July 11th
by Zacks Equity Research
AXSM, HIVE and TIMB made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 11, 2023.
Axsome (AXSM) Doses First Patient in Late-Stage ADHD Study
by Zacks Equity Research
Axsome (AXSM) doses its first patient in the late-stage, label expansion study of solriamfetol for treating attention deficit hyperactivity disorder.
Axsome (AXSM) Down on Public Offering of Common Stock
by Zacks Equity Research
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Axsome (AXSM) Soars 8.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Axsome (AXSM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Why Is Axsome (AXSM) Down 2.5% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome (AXSM) Q1 Earnings Beat Estimates, Auvelity Volume Rises
by Zacks Equity Research
Axsome (AXSM) incurs a narrower-than-expected loss in 1Q23. Its revenues beat estimates and stock gains.
Axsome Therapeutics (AXSM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of 80.53% and 252.03%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Focuses on Auvelity Launch to Fuel Its Growth
by Zacks Equity Research
Axsome's (AXSM) earnings benefit from the launch of Auvelity (AXS-05), meant for treating major depressive disorders.
Intra-Cellular's (ITCI) Caplyta Aids Sales, Overreliance a Woe
by Zacks Equity Research
Intra-Cellular (ITCI) is witnessing growth aided by its sole-marketed drug, Caplyta. However, the lack of other promising candidates in the pipeline is concerning.
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
3 Medical Stocks With Solid Growth Potential to Keep Track Of
by Indrajit Bandyopadhyay
Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.
Intra-Cellular (ITCI) Depression Drug Meets Study Goal, Stock Up
by Zacks Equity Research
Intra-Cellular Therapeutics (ITCI) announces positive top-line data from its phase III study evaluating lumateperone for the treatment of depression. Stock surges 16% following the news.
Axsome (AXSM) Down 9.8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome (AXSM) Stock Up 17% in Six Months: Here's Why
by Zacks Equity Research
Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
by Zacks Equity Research
Sector ETF report for PTH
Jazz's (JAZZ) Q4 Earnings Miss Estimates, New Drugs Drive Sales
by Zacks Equity Research
Jazz (JAZZ) reports dismal fourth-quarter results as earnings and sales miss expectations. Sleep disorder drug Xywav become the company's largest product by net sales during the quarter.
Axsome (AXSM) Q4 Earnings Miss, Auvelity Records First Sales
by Zacks Equity Research
Axsome Therapeutics (AXSM) incurs wider-than-expected loss in Q4 2022. Revenues beat estimates while shares gain.
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Axsome (AXSM) delivered earnings and revenue surprises of -8.47% and 13.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XPH
Should You Invest in the SPDR S&P Pharmaceuticals ETF (XPH)?
by Zacks Equity Research
Sector ETF report for XPH
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Axsome (AXSM) Rides on New Drug Approval & Sunosi Buyout
by Zacks Equity Research
Axsome (AXSM) receives FDA approval for Auvelity to treat major depressive disorder in August. The Sunosi deal and promising pipeline bode well. Stiff competition in the target market remains a woe.
3 Medical Stocks With Solid Growth Drivers to Keep Track Of
by Indrajit Bandyopadhyay
Here we discuss three medical stocks - AXSM, MRNA and ISRG - that have the potential to create wealth for investors over the coming years.
Why Is Axsome (AXSM) Up 18.6% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.